Preclinical studies have shown that nutlin-3a is broadly effective against cancer cells expressing TP53 either as a single agent55, 56, or in combination with chemotherapeutic agent, such as cisplatin in NPC, lung and ovarian cancer54, 55, 57. The gene discussed is TP53; the disease is nasopharyngeal carcinoma.